Rapport Therapeutics closed at $25.93 on Nov 4, up 1.93%, 50.6% below its 52-week closing high. Volume of 444.8K shares was 0.30× its 20-day average (below normal).
Split-adjusted performance: -16.8% over one month, -30.0% over six months, -3.7% over one year.
Short interest was 3.1M shares at the Oct 15 settlement, down 4.5% from the prior report (10.9% of float, 11.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RAPPRapport Therapeutics | $25.93 | +1.93% | −30.0% | — | — | — | $1.46B | |
| URGNUroGen Pharma | $29.81 | −13.34% | +13.6% | +199.2% | −19.8% | — | $1.46B | Compare |
| TYRATyra Biosciences | $21.31 | −0.30% | −37.0% | — | — | — | $1.46B | Compare |
| PCRXPacira BioSciences | $36.43 | +0.10% | +53.8% | +6.2% | 2.4% | 99.3 | $1.45B | Compare |
| MLYSMineralys Therapeutics | $16.67 | +4.22% | −44.7% | — | — | — | $1.47B | Compare |
| ETONEton Pharmaceutcials | $51.59 | +1.26% | +71.1% | +98.6% | 30.8% | 116.2 | $1.47B | Compare |
| ANABAnaptysBio | $47.35 | −0.80% | −29.7% | −8.0% | −206.9% | — | $1.42B | Compare |
| KARDKardigan | $14.99 | +4.68% | — | — | — | — | $1.40B | Compare |
| KRSAKorsana Biosciences | $30.55 | −4.43% | — | — | — | — | $1.39B | Compare |
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
